NYSE
BHVN

Biohaven Pharmaceutical Holding Co Ltd

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Biohaven Pharmaceutical Holding Co Ltd Stock Price

Vitals

Today's Low:
$18.41
Today's High:
$19.29
Open Price:
$18.47
52W Low:
$5.54
52W High:
$22.859
Prev. Close:
$18.73
Volume:
555879

Company Statistics

Market Cap.:
$1.48 billion
Book Value:
6.923
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
-83.93%
Return on Equity TTM:
-191.81%

Company Profile

Biohaven Pharmaceutical Holding Co Ltd had its IPO on 2022-09-23 under the ticker symbol BHVN.

The company operates in the Healthcare sector and Biotechnology industry. Biohaven Pharmaceutical Holding Co Ltd has a staff strength of 0 employees.

Stock update

Shares of Biohaven Pharmaceutical Holding Co Ltd opened at $18.47 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $18.41 - $19.29, and closed at $19.21.

This is a +2.56% increase from the previous day's closing price.

A total volume of 555,879 shares were traded at the close of the day’s session.

In the last one week, shares of Biohaven Pharmaceutical Holding Co Ltd have increased by +1.43%.

Biohaven Pharmaceutical Holding Co Ltd's Key Ratios

Biohaven Pharmaceutical Holding Co Ltd has a market cap of $1.48 billion, indicating a price to book ratio of 10.2225 and a price to sales ratio of 0.

In the last 12-months Biohaven Pharmaceutical Holding Co Ltd’s revenue was $0 with a gross profit of $0 and an EBITDA of $-524956000. The EBITDA ratio measures Biohaven Pharmaceutical Holding Co Ltd's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Biohaven Pharmaceutical Holding Co Ltd’s operating margin was 0% while its return on assets stood at -83.93% with a return of equity of -191.81%.

In Q1, Biohaven Pharmaceutical Holding Co Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Biohaven Pharmaceutical Holding Co Ltd’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-10.63 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Biohaven Pharmaceutical Holding Co Ltd’s profitability.

Biohaven Pharmaceutical Holding Co Ltd stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -2.4123. Its price to sales ratio in the trailing 12-months stood at 0.

Biohaven Pharmaceutical Holding Co Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$618.52 million
Total Liabilities
$114.01 million
Operating Cash Flow
$0
Capital Expenditure
$735000
Dividend Payout Ratio
0%

Biohaven Pharmaceutical Holding Co Ltd ended 2024 with $618.52 million in total assets and $0 in total liabilities. Its intangible assets were valued at $618.52 million while shareholder equity stood at $472.26 million.

Biohaven Pharmaceutical Holding Co Ltd ended 2024 with $0 in deferred long-term liabilities, $114.01 million in other current liabilities, 616246000.00 in common stock, $-161616000.00 in retained earnings and $1.39 million in goodwill. Its cash balance stood at $125.03 million and cash and short-term investments were $388.03 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Biohaven Pharmaceutical Holding Co Ltd’s total current assets stands at $544.48 million while long-term investments were $0 and short-term investments were $263.00 million. Its net receivables were $43.83 million compared to accounts payable of $14.46 million and inventory worth $0.

In 2024, Biohaven Pharmaceutical Holding Co Ltd's operating cash flow was $0 while its capital expenditure stood at $735000.

Comparatively, Biohaven Pharmaceutical Holding Co Ltd paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$19.21
52-Week High
$22.859
52-Week Low
$5.54
Analyst Target Price
$25

Biohaven Pharmaceutical Holding Co Ltd stock is currently trading at $19.21 per share. It touched a 52-week high of $22.859 and a 52-week low of $22.859. Analysts tracking the stock have a 12-month average target price of $25.

Its 50-day moving average was $21.08 and 200-day moving average was $17.48 The short ratio stood at 10.7 indicating a short percent outstanding of 0%.

Around 1461.3% of the company’s stock are held by insiders while 9477.4% are held by institutions.

Frequently Asked Questions About Biohaven Pharmaceutical Holding Co Ltd

The stock symbol (also called stock or share ticker) of Biohaven Pharmaceutical Holding Co Ltd is BHVN

The IPO of Biohaven Pharmaceutical Holding Co Ltd took place on 2022-09-23

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$57.45
0.85
+1.5%
$65.59
0.57
+0.88%
$25.7
-0.2
-0.77%
U.S. Bancorp (USB-PS)
$19.02
0.04
+0.21%
$34.04
0.1
+0.29%
POKARNA LTD. (POKARNA)
$490.15
-60.55
-11%
$444.95
-22.05
-4.72%
$322
-27.55
-7.88%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company’s pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; BHV-7010, a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an oral myeloperoxidase inhibitor, which is in Phase 3 clinical trial for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa, an anti-myostatin adnectin, which is in Phase 3 clinical trial for the treatment of spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.

Address

215 Church Street, New Haven, CT, United States, 06510